The results indicated that atezolizumab plus albumin-bound paclitaxel raised progression-free survival in the intention-to-treat population and the PD-L1-positive subgroup of patients with metastatic triple-negative breast cancer (18). Here, CD274 is linked to triple-negative breast carcinoma.